Endometrial Cancer Is the Most Common Type of Uterine Cancer

Over the last 10 years, rates of new cases and deaths have been rising on average each year

<table>
<thead>
<tr>
<th>Increase in new cases</th>
<th>Increase in deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.3%</td>
<td>1.6%</td>
</tr>
</tbody>
</table>

Endometrial cancers account for more than **90%** of all **UTERINE CANCERS**, the most common gynecologic cancer in the United States

Uterine sarcomas, ≤10%

Most Cases Are Diagnosed at an Early Stage, Leading to Higher Survival

- **90%** of women diagnosed with EC present with abnormal vaginal bleeding
- 5-year relative survival rate for localized disease: **94.9%**

Patients With Advanced Disease Have a Worse Prognosis

- 5-year relative survival rate for regional disease: **68.6%**
- 5-year relative survival rate for distant disease: **16.3%**

Treatment for early-stage disease generally involves some combination of:

- Surgery
- Radiation Therapy
- Chemotherapy

Options for systemic therapy in advanced or recurrent endometrial cancer include:

- Chemotherapy
- Biologic Therapy/Immunotherapy
- Hormone Therapy

Early diagnosis is critical, as outcomes are poor for women diagnosed with metastatic EC

Management varies by stage and may include surgery, radiation, and/or systemic therapies

Ongoing research is exploring development of new combinations and targeted therapies

For additional content on this topic, please visit [www.GemstoneOncology.com](http://www.GemstoneOncology.com)

---

References:

---

90% of women diagnosed with EC present with abnormal vaginal bleeding

Most Cases Are Diagnosed at an Early Stage, Leading to Higher Survival

- 5-year relative survival rate for localized disease: **94.9%**

Patients With Advanced Disease Have a Worse Prognosis

- 5-year relative survival rate for regional disease: **68.6%**
- 5-year relative survival rate for distant disease: **16.3%**

Early diagnosis is critical, as outcomes are poor for women diagnosed with metastatic EC

Management varies by stage and may include surgery, radiation, and/or systemic therapies

Ongoing research is exploring development of new combinations and targeted therapies

For additional content on this topic, please visit [www.GemstoneOncology.com](http://www.GemstoneOncology.com)